切换至 "中华医学电子期刊资源库"

第五届中国出版政府奖音像电子网络出版物奖提名奖

中国科技核心期刊

中国科学引文数据库(CSCD)来源期刊

中华重症医学电子杂志 ›› 2026, Vol. 12 ›› Issue (01) : 7 -14. doi: 10.3877/cma.j.issn.2096-1537.2026.01.002

专题笔谈

慢病脓毒症的疾病负担及研究现状
史楠, 于瑞璇, 谢剑锋, 邱海波()   
  1. 210009 南京,江苏省重症医学重点实验室 东南大学附属中大医院重症医学科
  • 收稿日期:2025-11-14 出版日期:2026-02-28
  • 通信作者: 邱海波
  • 基金资助:
    四大慢病重大专项(2023ZD0506500,2023ZD0506506)

Disease burden and current research status in sepsis with chronic comorbidities

Nan Shi, Ruixuan Yu, Jianfeng Xie, Haibo Qiu()   

  1. Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China
  • Received:2025-11-14 Published:2026-02-28
  • Corresponding author: Haibo Qiu
引用本文:

史楠, 于瑞璇, 谢剑锋, 邱海波. 慢病脓毒症的疾病负担及研究现状[J/OL]. 中华重症医学电子杂志, 2026, 12(01): 7-14.

Nan Shi, Ruixuan Yu, Jianfeng Xie, Haibo Qiu. Disease burden and current research status in sepsis with chronic comorbidities[J/OL]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2026, 12(01): 7-14.

脓毒症是一种危及生命的临床综合征,病死率高。慢性疾病(简称慢病)是影响脓毒症临床过程及预后的重要因素之一。慢病在脓毒症患者中较常见,且慢病脓毒症患者在免疫反应与血管功能方面表现出相对特异的生理特征。此外,在近远期预后方面,慢病脓毒症通常面临更高的病死率及更差的生活质量。在治疗方面,合并不同类型慢病的脓毒症主要在抗感染治疗、液体复苏及器官功能支持等方面存在不确定性。同时,积极持续的ICU后管理有重要价值。本文就慢病脓毒症的疾病负担及研究现状展开综述,旨在为今后相关机制研究及精准治疗提供理论依据。

Sepsis is a life-threatening clinical syndrome with a high mortality rate globally. Chronic comorbidities are important factors influencing the clinical course and prognosis of sepsis. Chronic comorbidities are highly prevalent among sepsis patients, and those with chronic diseases exhibit relatively distinct physiological characteristics in immune response and vascular function. Moreover, patients with chronic comorbidities face higher mortality and poorer quality of life. In terms of treatment, uncertainty remains regarding the management of sepsis in patients with different types of comorbidities, particularly concerning anti-infection treatment, fluid resuscitation, and multiorgan support. Meanwhile, active and continuous post-ICU management is of great value. This review summarizes the disease burden and current research status of sepsis in patients with chronic comorbidities, aiming to provide a theoretical basis and reference for future mechanistic researches and precision treatment.

1
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) [J]. JAMA, 2016, 315(8): 801-810.
2
Centers for Disease Control and Prevention. About chronic diseases [EB/OL]. (2025-03-04) [2025-11-01].
3
Weng L, Xu Y, Yin P, et al. National incidence and mortality of hospitalized sepsis in China [J]. Crit Care, 2023, 27: 84.
4
Mellhammar L, Wollter E, Dahlberg J, et al. Estimating sepsis incidence using administrative data and clinical medical record review [J]. JAMA netw open, 2023, 6(8): e2331168.
5
Danai PA, Moss M, Mannino DM, et al. The epidemiology of sepsis in patients with malignancy [J]. Chest, 2006, 129(6): 1432-1440.
6
Lee EH, Lee KH, Lee KN, et al. Connection between impaired fasting glucose or type 2 diabetes mellitus and sepsis: a 10-year observational data from the National Health Screening Cohort [J]. Diabetes Metab J, 2025, 49(3): 485-497.
7
Galbois A, Aegerter P, Martel-samb P, et al. Improved prognosis of septic shock in patients with cirrhosis: a multicenter study [J]. Crit Care Med, 2014, 42(7): 1666-1675.
8
Hensley MK, Donnelly JP, Carlton EF, et al. Epidemiology and outcomes of cancer-related versus non-cancer-related sepsis hospitalizations [J]. Crit Care Med, 2019, 47(10): 1310-1316.
9
Mirouse A, Vigneron C, Llitjos JF, et al. Sepsis and cancer: an interplay of friends and foes [J]. Am J Respir Crit Care Med, 2020, 202(12): 1625-1635.
10
Holt RIG, Cockram CS, Ma RCW, et al. Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment [J]. Diabetologia, 2024, 67(7): 1168-1180.
11
Fernández J, Navasa M, Gómez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis [J]. Hepatology, 2002, 35(1): 140-148.
12
Wasmuth HE, Kunz D, Yagmur E, et al. Patients with acute on chronic liver failure display “sepsis-like” immune paralysis [J]. J Hepatol, 2005, 42(2): 195-201.
13
Syed-Ahmed M, Narayanan M. Immune dysfunction and risk of infection in chronic kidney disease [J]. Adv Chronic Kidney Dis, 2019, 26(1): 8-15.
14
Walker AMN, Drozd M, Hall M, et al. Prevalence and predictors of sepsis death in patients with chronic heart failure and reduced left ventricular ejection fraction [J]. J Am Heart Assoc, 2018, 7(20): e009684.
15
Yndestad A, Damås JK, Oie E, et al. Systemic inflammation in heart failure--the whys and wherefores [J]. Heart Fail Rev, 2006, 11(1): 83-92.
16
Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis [J]. Lancet, 2015, 386(9990): 258-265.
17
Bruno RM, Masi S, Taddei M, et al. Essential hypertension and functional microvascular ageing [J]. High Blood Press Cardiovasc Prev, 2018, 25(1): 35-40.
18
Gupta V, Sachdeva S, Khan AS, et al. Endothelial dysfunction and inflammation in different stages of essential hypertension [J]. Saudi J Kidney Dis Transpl, 2011, 22(1): 97-103.
19
Bermejo-martin JF, Martín-fernandez M, López-mestanza C, et al. Shared features of endothelial dysfunction between sepsis and its preceding risk factors (aging and chronic disease) [J]. J Clin Med, 2018, 7(11): 400.
20
Yang Y, Yang KS, Hsann YM, et al. The effect of comorbidity and age on hospital mortality and length of stay in patients with sepsis [J]. J Crit Care, 2010, 25(3): 398-405.
21
Cuenca JA, Manjappachar NK, Ramírez CM, et al. Outcomes and predictors of 28-day mortality in patients with solid tumors and septic shock defined by Third International Consensus Definitions for sepsis and septic shock criteria [J]. Chest, 2022, 162(5): 1063-1073.
22
Nazer L, Lopez-olivo MA, Cuenca JA, et al. All-cause mortality in cancer patients treated for sepsis in intensive care units: a systematic review and meta-analysis [J]. Supportive Care Cancer, 2022, 30(12): 10099-10109.
23
Lu B, Xu Y, Li N, et al. Overall and geographic pattern of incidence, fatality and mortality of sepsis among hospitalized non-child cancer patients in China: a nationwide cross-sectional study [J]. Sci Bull (Beijing), 2024, 69(11): 1637-1641.
24
Manjappachar NK, Cuenca JA, Ramírez CM, et al. Outcomes and predictors of 28-day mortality in patients with hematologic malignancies and septic shock defined by Sepsis-3 criteria [J]. J Natl Compr Canc Netw, 2022, 20(1): 45-53.
25
Vincent F, Soares M, Mokart D, et al. In-hospital and day-120 survival of critically ill solid cancer patients after discharge of the intensive care units: results of a retrospective multicenter study-A Groupe de recherche respiratoire en réanimation en Onco-Hématologie (Grrr-OH) study [J]. Ann Intensive Care, 2018, 8(1): 40.
26
Sipilä PN, Lindbohm JV, Batty GD, et al. Severe infection and risk of cardiovascular disease: a multicohort study [J]. Circulation, 2023, 147(21): 1582-1593.
27
Liu L, Huang P, Wang C, et al. Causal association between heart failure and sepsis: insights from Mendelian randomization and observational studies [J]. Clin Epidemiol, 2024, 16: 755-767.
28
Sakhuja A, Nanchal RS, Gupta S, et al. Trends and outcomes of severe sepsis in patients on maintenance dialysis [J]. Am J Nephrol, 2016, 43(2): 97-103.
29
Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population [J]. Kidney Int, 2000, 58(4): 1758-1764.
30
van der SEC, Beumeler LFE, Holmqvist M, et al. Understanding post-sepsis syndrome: how can clinicians help? [J]. Infect Drug Resist, 2023, 16: 6493-6511.
31
Kim JS, Kim YJ, Kim YJ, et al. Impact of developing dialysis-requiring acute kidney injury on long-term mortality in cancer patients with septic shock [J]. Cancers (Basel), 2023, 15(14): 3619.
32
Bianchi A, Mokart D, Leone M. Cancer and sepsis: future challenges for long-term outcome [J]. Curr Opin Crit Care, 2024, 30(5): 495-501.
33
Ou SM, Chu H, Chao PW, et al. Long-term mortality and major adverse cardiovascular events in sepsis survivors. A Nationwide Population-based Study [J]. Am J Respir Crit Care Med, 2016, 194(2): 209-217.
34
Yende S, Linde-zwirble W, Mayr F, et al. Risk of cardiovascular events in survivors of severe sepsis [J]. Am J Respir Crit Care Med, 2014, 189(9): 1065-1074.
35
Angriman F, Rosella LC, Lawler PR, et al. Sepsis hospitalization and risk of subsequent cardiovascular events in adults: a population-based matched cohort study [J]. Intensive Care Med, 2022, 48(4): 448-457.
36
Zheng J, Ni C, Lee SWR, et al. Association of hospital-treated infectious diseases and infection burden with cardiovascular diseases and life expectancy [J]. J Intern Med, 2024, 295(5): 679-694.
37
Angriman F, Lawler PR, Shah BR, et al. Prevalent diabetes and long-term cardiovascular outcomes in adult sepsis survivors: a population-based cohort study [J]. Crit Care, 2023, 27: 302.
38
Arshad A, Ayaz A, Rehman S, et al. Progression of acute kidney injury to chronic kidney disease in sepsis survivors: 1-year follow-up study [J]. J Intensive Care Med, 2021, 36(11): 1366-1370.
39
Schulman IH, Chan K, Der JS, et al. Readmission and mortality after hospitalization with acute kidney injury [J]. Am J Kidney Dis, 2023, 82(1): 63-74.
40
Mankowski RT, Anton SD, Ghita GL, et al. Older sepsis survivors suffer persistent disability burden and poor long-term survival [J]. J Am Geriatr Soc, 2020, 68(9): 1962-1969.
41
Yende S, Kellum JA, Talisa VB, et al. Long-term host immune response trajectories among hospitalized patients with sepsis [J]. JAMA Netw Open, 2019, 2(8): e198686.
42
Soussi S, Sharma D, Jüni P, et al. Identifying clinical subtypes in sepsis-survivors with different one-year outcomes: a secondary latent class analysis of the FROG-ICU cohort [J]. Crit Care, 2022, 26(1): 114.
43
Shimazui T, Nakada TA, Walley KR, et al. Significance of body temperature in elderly patients with sepsis [J]. Crit Care, 2020, 24(1): 387.
44
Garami A, Steiner AA, Romanovsky AA. Fever and hypothermia in systemic inflammation [J]. Handb Clin Neurol, 2018, 157: 565-597.
45
Laborde C, Bador J, Hacquin A, et al. Atypical presentation of bacteremic urinary tract infection in older patients: frequency and prognostic impact [J]. Diagnostics (Basel), 2021, 11(3): 523.
46
Janssens JP, Krause KH. Pneumonia in the very old [J]. Lancet Infect Dis, 2004, 4(2): 112-124.
47
Goodacre S, Fuller G, Conroy S, et al. Diagnosis and management of sepsis in the older adult [J]. BMJ, 2023: e075585.
48
Putot A, Prendki V. New horizons in sepsis management in older patients [J]. Age Ageing, 2023, 52(2): afad016.
49
Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock [J]. Crit Care Med, 2006, 34(6): 1589-1596.
50
Hechtman RK, Kipnis P, Cano J, et al. Heterogeneity of benefit from earlier time-to-antibiotics for sepsis [J]. Am J Respir Crit Care Med, 2024, 209(7): 852-860.
51
Mokart D, Saillard C, Sannini A, et al. Neutropenic cancer patients with severe sepsis: need for antibiotics in the first hour [J]. Intensive Care Med, 2014, 40(8): 1173-1174.
52
Mokart D, Slehofer G, Lambert J, et al. De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study [J]. Intensive Care Med, 2014, 40(1): 41-49.
53
Urina Jassir D, Chaanine AH, Desai S, et al. Therapeutic dilemmas in mixed septic-cardiogenic shock [J]. Am J Med, 2023, 136(1): 27-32.
54
Maiwall R, Rao Pasupuleti SS, Hidam AK, et al. A randomised-controlled trial (TARGET-C) of high vs. low target mean arterial pressure in patients with cirrhosis and septic shock [J]. J Hepatol, 2023, 79(2): 349-361.
55
Philips CA, Maiwall R, Sharma MK, et al. Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis (FRISC study): a randomized controlled trial [J]. Hepatol Int, 2021, 15(4): 983-994.
56
Henriksen JH, Bendtsen F, Sørensen TI, et al. Reduced central blood volume in cirrhosis [J]. Gastroenterology, 1989, 97(6): 1506-1513.
57
Durand F, Kellum JA, Nadim MK. Fluid resuscitation in patients with cirrhosis and sepsis: a multidisciplinary perspective [J]. J Hepatol, 2023, 79(1): 240-246.
58
Pence M, Tran QK, Shesser R, et al. Outcomes of CMS-mandated fluid administration among fluid-overloaded patients with sepsis: a systematic review and meta-analysis [J]. Am J Emerg Med, 2022, 55: 157-166.
59
Powell RE, Kennedy JN, Senussi MH, et al. Association between preexisting heart failure with reduced ejection fraction and fluid administration among patients with sepsis [J]. JAMA Netw Open, 2022, 5(10): e2235331.
60
Rourke EM, Kuttab HI, Lykins JD, et al. Fluid resuscitation in septic patients with comorbid heart failure [J]. Crit Care Med, 2021, 49(2): e201-e204.
61
Jorda A, Douglas IS, Staudinger T, et al. Fluid management for sepsis-induced hypotension in patients with advanced chronic kidney disease: a secondary analysis of the CLOVERS trial [J]. Crit Care, 2024, 28(1): 231.
62
The National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Clinical Trials Network. Early restrictive or liberal fluid management for sepsis-induced hypotension [J]. N Engl J Med, 2023, 388(6): 499-510.
63
Khan RA, Khan NA, Bauer SR, et al. Association between volume of fluid resuscitation and intubation in high-risk patients with sepsis, heart failure, end-stage renal disease, and cirrhosis [J]. Chest, 2020, 157(2): 286-292.
64
Bharwani A, Dionne JC, Pérez ML, et al. Conservative versus liberal fluid resuscitation for septic patients at risk for fluid overload: a systematic review with meta-analysis [J]. J Crit Care, 2025, 87: 155045.
65
Corl KA, Levy MM, Holder AL, et al. Moderate Ⅳ fluid resuscitation is associated with decreased sepsis mortality [J]. Crit Care Med, 2024, 52(11): e557-e567.
66
Liu VX, Morehouse JW, Marelich GP, et al. Multicenter implementation of a treatment bundle for patients with sepsis and intermediate lactate values [J]. Am J Respir Crit Care Med, 2016, 193(11): 1264-1270.
67
ANDROMEDA-SHOCK-2 Investigators for the ANDROMEDA Research Network, Spanish Society of Anesthesiology, Reanimation and Pain Therapy (SEDAR), and Latin American Intensive Care Network (LIVEN), et al. Personalized hemodynamic resuscitation targeting capillary refill time in early septic shock: the ANDROMEDA-SHOCK-2 randomized clinical trial [J]. JAMA, 2025, 334(22): 1988-1999.
68
Demiselle J, Ferrer R, Besen B. Hemodynamic targets in the initial resuscitation of older patients with sepsis: time for a reappraisal? [J]. Intensive Care Med, 2025, 51(8): 1518-1521.
69
Endo A, Yamakawa K, Tagami T, et al. Efficacy of targeting high mean arterial pressure for older patients with septic shock (OPTPRESS): a multicentre, pragmatic, open-label, randomised controlled trial [J]. Intensive Care Med, 2025, 51(5): 883-892.
70
Lamontagne F, Richards-belle A, Thomas K, et al. Effect of reduced exposure to vasopressors on 90-day mortality in older critically ill patients with vasodilatory hypotension: a randomized clinical trial [J]. JAMA, 2020, 323(10): 938-949.
71
Smith TN, Choi C, Rattan P, et al. Serum lactate and mean arterial pressure thresholds in patients with cirrhosis and septic shock [J]. Hepatol Commun, 2024, 8(1): e0353.
72
Dewitte A, Labat A, Duvignaud PA, et al. High mean arterial pressure target to improve sepsis-associated acute kidney injury in patients with prior hypertension: a feasibility study [J]. Ann Intensive Care, 2021, 11(1): 139.
73
Hernández G, Ospina-tascón GA, Damiani LP, et al. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: the ANDROMEDA-SHOCK randomized clinical trial [J]. JAMA, 2019, 321(7): 654-664.
74
Delaney A, Borges-Sa M, Chew MS, et al. Current standard of care for septic shock [J]. Intensive Care Med, 2026, 52(1): 89-103.
75
Mikkelsen ME, Still M, Anderson BJ, et al. Society of Critical Care Medicine's International Consensus Conference on prediction and identification of long-term impairments after critical illness [J]. Crit Care Med, 2020, 48(11): 1670-1679.
76
Bakhru RN, Flores L, Cain JM, et al. A randomized controlled trial of a post-ICU Telehealth Care Model (WFIT) [J]. Am J Respir Crit Care Med, 2025, 211(9): 1662-1670.
77
Schofield-Robinson OJ, Lewis SR, Smith AF, et al. Follow-up services for improving long-term outcomes in intensive care unit (ICU) survivors [J]. Cochrane Database Syst Rev, 2018, 11(11): CD012701.
78
Sharshar T, Grimaldi-Bensouda L, Siami S, et al. A randomized clinical trial to evaluate the effect of post-intensive care multidisciplinary consultations on mortality and the quality of life at 1 year [J]. Intensive Care Med, 2024, 50(5): 665-677.
79
Rosa RG, Walsh TS. Navigating complex interventions in post-ICU care: insights from a randomized clinical trial of post-intensive care multidisciplinary consultations [J]. Intensive Care Med, 2024, 50(5): 725-727.
80
Jones C, Eddleston J, McCairn A, et al. Improving rehabilitation after critical illness through outpatient physiotherapy classes and essential amino acid supplement: a randomized controlled trial [J]. J Crit Care, 2015, 30(5): 901-907.
[1] 张永宏, 徐玉沙, 邓如非, 姜臻宇, 张友来, 邹立津, 辛国华. 非药物干预疗法减轻烧伤患者疼痛的研究进展[J/OL]. 中华损伤与修复杂志(电子版), 2026, 21(02): 127-131.
[2] 樊伟伟, 许怀利, 杨喜佳. 中间入路与左侧前入路在中老年进展期胃癌腹腔镜根治术中的应用对比[J/OL]. 中华普外科手术学杂志(电子版), 2026, 20(02): 117-120.
[3] 李广鑫, 权慧娟, 高志娟, 李良, 王肖君, 曹玉庆. 腹腔镜急诊切除与支架置入限期切除治疗梗阻性结直肠癌的临床效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2026, 20(02): 142-145.
[4] 李坚, 张伟, 曾少杰, 母德安. 经皮穿刺消融治疗与腹腔镜肝脏切除术治疗早期肝内胆管癌的临床效果对比研究[J/OL]. 中华普外科手术学杂志(电子版), 2026, 20(02): 187-190.
[5] 李俊杰, 董培, 姚成, 刘泽, 李勇. 前列腺癌免疫治疗的研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(02): 209-215.
[6] 周明宽, 罗程, 庄锦涛, 涂响安. 广东省医学会泌尿外科疑难病例多学科会诊(第28期)——阴茎癌并双侧腹股沟、髂外动脉旁淋巴结转移[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(02): 231-236.
[7] 谢伟, 张小峰, 沈锋. 肿瘤免疫治疗相关不良事件的流行病学特征、发生机制和防治策略[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(02): 146-151.
[8] 崔梦玲, 孙文梅, 赵睿敏, 王家平. 合并微血管侵犯肝癌术后TACE联合治疗的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(02): 160-166.
[9] 邓玉飞, 王志鑫, 娄珂, 张林轩, 马桂春, 港措. 影像组学在肝癌精准诊断、疗效评估及治疗方案决策优化中应用[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(02): 172-180.
[10] 吴杰嵘, 严庆, 胡健垣, 陈焕伟. 复发性肝细胞癌再次手术切除与射频消融临床疗效比较[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(02): 211-218.
[11] 常莉娜, 刘囡囡. DWI联合DCE-MRI定量参数对局部进展期直肠癌新辅助治疗后病理完全缓解的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2026, 16(02): 125-129.
[12] 王明辉, 李文波, 李群, 马增翼, 吴文明, 王静, 孙奎林, 张保娟, 刘晓峰. 早期内镜止血治疗在胃底静脉曲张组织胶注射后排胶溃疡出血中的应用[J/OL]. 中华消化病与影像杂志(电子版), 2026, 16(02): 151-155.
[13] 宋文迪, 孙蔚, 宋海庆. 脑卒中后平衡障碍的发生机制及治疗的研究进展[J/OL]. 中华脑血管病杂志(电子版), 2026, 20(02): 111-118.
[14] 单子恒, 王帆, 马丽, 张涛, 邵丽. 头颈部CT血管成像联合头颅CT灌注成像评估急性缺血性脑卒中患者短期预后的效能[J/OL]. 中华脑血管病杂志(电子版), 2026, 20(02): 164-169.
[15] 李丽娜, 彭滢, 巩俪, 郑志东. 血清脂蛋白(a)、载脂蛋白B/载脂蛋白A1比值与急性脑梗死阿替普酶静脉溶栓治疗预后的关系[J/OL]. 中华脑血管病杂志(电子版), 2026, 20(02): 178-184.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?